Natalizumab: Bound to rebound?

Neurology

Volumn 72, Issue 5, 2009, Pages 392-393

  Schiess, Nicoline ^a   Calabresi, Peter A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NATALIZUMAB; PLACEBO; TRANSCRIPTION FACTOR FOXP3; VERY LATE ACTIVATION ANTIGEN 4; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

CELL MIGRATION; CENTRAL NERVOUS SYSTEM INFECTION; EDITORIAL; HUMAN; JC VIRUS; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REGULATORY T LYMPHOCYTE; RISK FACTOR; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECT; IMMUNOLOGY; LEUKOCYTOSIS; LYMPHOCYTE; METHODOLOGY; NEUTROPHIL CHEMOTAXIS; NOTE; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; STATISTICS; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; CHEMOTAXIS, LEUKOCYTE; CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKOCYTOSIS; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; LYMPHOCYTES; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT (HEALTH CARE); TREATMENT OUTCOME;

EID: 61549089098     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/01.wnl.0000341783.33962.5b     Document Type: Editorial

References (5)

1. Ransohoff RM. Natalizumab and PML. Nat Neurosci 2005;8:1275.
2. Vellinga MM, Castelijns JA, Barkhoff F, Uitdehaag BMJ, Polman CH. Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated patients. Neurology 2008;70:1150-1151.
3. Tubridy N, Behan PO, Capildeo R, et al. The effect of anti-α4 integrin antibody on brain lesion activity in MS. Neurology 1999;53:466-472.
4. Miller DH, Khan OA, Sheremata WA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003;348:15-23.
5. Stüve O, Cravens PD, Frohman EM, et al. Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy. Neurology 2009;72:404-409.